CureVac N.V. (CVAC)
Jan 6, 2026 - CVAC was delisted (reason: acquired by BNTX)
4.660
-0.010 (-0.21%)
Inactive · Last trade price
on Jan 5, 2026
CureVac Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for CureVac stock had an average target of 6.83, with a low estimate of 5.00 and a high estimate of 10.
Analyst Consensus: Hold
* Price targets were last updated on Jun 26, 2025.
Analyst Ratings
The average analyst rating for CureVac stock from 3 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy → Hold Downgrades $12 → $5.5 | Strong Buy → Hold | Downgrades | $12 → $5.5 | +18.03% | Jun 26, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $7 → $5 | Strong Buy → Hold | Downgrades | $7 → $5 | +7.30% | Jun 13, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $10 | Buy | Reiterates | $10 | +114.59% | May 28, 2025 |
| UBS | UBS | Strong Buy Maintains $13 → $12 | Strong Buy | Maintains | $13 → $12 | +157.51% | Apr 30, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $16 | Buy | Reiterates | $16 | +243.35% | Feb 14, 2025 |
Financial Forecast
Revenue This Year
72.69M
from 535.18M
Decreased by -86.42%
Revenue Next Year
89.92M
from 72.69M
Increased by 23.71%
EPS This Year
-0.47
from 0.72
EPS Next Year
-0.44
from -0.47
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 110.3M | 111.3M | ||||
| Avg | 72.7M | 89.9M | ||||
| Low | 33.5M | 60.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -79.4% | 53.1% | ||||
| Avg | -86.4% | 23.7% | ||||
| Low | -93.7% | -17.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.13 | -0.16 | |
| Avg | -0.47 | -0.44 | |
| Low | -0.70 | -0.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.